The 4-(N-dichloroacetyl-N-methylamino)benzyloxymethyl group for 2′-hydroxyl protection of ribonucleosides in the solid-phase synthesis of oligoribonucleotides

Journal of Organic Chemistry

Volumn 73, Issue 7, 2008, Pages 2774-2783

  Cieślak, Jacek ^a   Grajkowski, Andrzej ^a   Kauffman, Jon S ^b   Duff, Robert J ^b   Beaucage, Serge L ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Lancaster Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME ACTIVITY; ORGANIC COMPOUNDS; RNA; SYNTHESIS (CHEMICAL);

OLIGORIBONUCLEOTIDES; SOLID PHASE SYNTHESIS;

NUCLEOTIDES;

ACETAL DERIVATIVE; ALKALINE PHOSPHATASE; METHYL GROUP; OLIGORIBONUCLEOTIDE; PHOSPHODIESTERASE; PHOSPHORAMIDOUS ACID DERIVATIVE; RIBONUCLEOSIDE; TETRAZOLE DERIVATIVE;

ARTICLE; CATALYSIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; RNA SEQUENCE; SOLID PHASE SYNTHESIS;

ACETANILIDES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; MOLECULAR STRUCTURE; OLIGORIBONUCLEOTIDES; ORGANOPHOSPHORUS COMPOUNDS; RIBONUCLEOSIDES; TIME FACTORS;

EID: 41649103104     PISSN: 00223263     EISSN: None     Source Type: Journal    
DOI: 10.1021/jo702717g     Document Type: Article

References (55)

1. Fire, A.; Xu, S.; Montgomery, M. K.; Kostas, S. A.; Driver, S. E.; Mello, C. C. Nature 1998, 391, 806-811.
2. Elbashir, S. M.; Harborth, J.; Lendeckel, W.; Yalcin, A.; Weber, K.; Tuschl, T. Nature 2001, 411, 494-498.
3. Dorsett, Y.; Tuschl, T. Nat. Rev. Drug Discovery 2004, 3, 318-329.
4. For excellent reviews on the mechanistic aspects of RNAi, see: (a) Bumcrot, D.; Manoharan, M.; Koteliansky, V.; Sah, D. W. Y. Nature Chem. Biol. 2006, 2, 711-719.
5. (b) Manoharan, M. Curr. Opin. Chem. Biol. 2004, 8, 570-579.
6. (c) Chiu, Y.-L.; Rana, T. M. Mol. Cell 2002, 10, 549-561.
7. (d) Kim, D. H.; Rossi, J. J. Nature Rev. Genet. 2007, 8, 173-184.
8. Bartel, D. P. Cell 2004, 116, 281-297.
9. Lee, Y.; Ahn, C.; Han, J.; Choi, H.; Kim, J.; Yim, J.; Lee, J.; Provost, P.; Radmark, O.; Kim, S.; Kim, V. N. Nature 2003, 425, 415-419.
10. Hammond, S. M. Trends Mol. Med. 2006, 12, 99-101.
11. Krützfeldt, J.; Rajewsky, N.; Braich, R.; Rajeev, K. G.; Tuschl, T.; Manoharan, M.; Stoffel, M. Nature 2005, 438, 685-689 and references therein.
12. Reese, C. B. Org. Biomol. Chem. 2005, 3, 3851-3868.
13. (b) Müller, S.; Wolf, G.; Ivanov, S. A. Curr. Org. Synth. 2004, 1, 293-307.
14. (c) Marshall, W. S.; Kaiser, R. J. Curr. Opin. Chem. Biol. 2004, 8, 222-229.
15. (d) Reese, C. B. Tetrahedron 2002, 58, 8893-8920.
16. (e) Reese, C. B. In Current Protocols in Nucleic Acid Chemistry; Beaucage, S. L., Bergstrom, D. E., Glick, G. D., Jones, R. A., Eds.; John Wiley & Sons: New York, 2000; Vol. I, pp 2.2.1-2.2.24.
17. (f) Pitsch, S. Chimia 2001, 55, 320-324.
18. (g) Beaucage, S. L.; Iyer, R. P. Tetrahedron 1992, 48, 2223-2311.
19. (a) Schwartz, M. E.; Breaker, R. R.; Asteriadis, G. T.; deBear, J. S.; Gough, G. R. Bioorg. Med. Chem. Lett. 1992, 2, 1019-1024.
20. (b) Miller, T. J.; Schwartz, M. E.; Gough, G. R. In Current Protocols in Nucleic Acid Chemistry; Beaucage, S. L., Bergstrom, D. E., Glick, G. D., Jones, R. A., Eds.; John Wiley & Sons: New York, 2000; Vol. I, pp 2.5.1-2.5.36 and pp 3.7.1-3.7.8.
21. Gough, G. R.; Miller, T. J.; Mantick, N. A. Tetrahedron Lett. 1996, 37, 981-982.
22. (a) Wincott, F. E.; Usman, N. Tetrahedron Lett. 1994, 35, 6827-6830.
23. (b) Wada, T.; Tobe, M.; Nagayama, T.; Furusawa, K.; Sekine, M. Tetrahedron Lett. 1995, 36, 1683-1684.
24. Lloyd, W.; Reese, C. B.; Song, Q.; Vandersteen, A. M.; Visintin, C.; Zhang, P.-Z. J. Chem. Soc., Perkin Trans. 1 2000, 165-176.
25. (a) Pitsch, S.; Weiss, P. A.; Jenny, L.; Stutz, A.; Wu, X. Helv. Chim. Acta 2001, 84, 3773-3795.
26. (b) Pitsch, S.; Weiss, P. A. In Current Protocols in Nucleic Acid Chemistry; Beaucage, S. L., Bergstrom, D. E., Glick, G. D., Jones, R. A., Eds.; John Wiley & Sons: New York, 2001; Vol. I, pp 2.9.1-2.9.14 and 3.8.1-3.8.15.
27. Matysiak, S.; Pfleiderer, W. Helv. Chim. Acta 2001, 84, 1066-1085.
28. Umemoto, T.; Wada, T. Tetrahedron Lett. 2004, 45, 9529-9531.
29. (a) Ohgi, T.; Masutomi, Y.; Ishiyama, K.; Kitagawa, H.; Shiba, Y.; Yano, J. Org. Lett. 2005, 7, 3477-3480.
30. (b) Shiba, Y.; Masuda, H.; Watanabe, N.; Ego, T.; Takagaki, K.; Ishiyama, K.; Ohgi, T.; Yano, J. Nucleic Acids Res. 2007, 35, 3287-3296.
31. Lackey, J. G.; Sabatino, D.; Damha, M. J. Org. Lett. 2007, 9, 789-792.
32. Semenyuk, A.; Földesi, A.; Johansson, T.; Estmer-Nilsson, C.; Blomgren, P.; Brännvall, M.; Kirsebom, L. A.; Kwiatkowski, M. J. Am. Chem. Soc. 2006, 128, 12356-12357.
33. Parey, N.; Baraguey, C.; Vasseur, J.-J.; Debart, F. Org. Lett. 2006, 8, 3869-3872.
34. (a) Marshall, W. S.; Kaiser, R. J. Curr. Opin. Chem. Biol. 2004, 8, 222-229.
35. (b) Scaringe, S. A.; Kitchen, D.; Kaiser, R. J.; Marshall, W. S. In Current Protocols in Nucleic Acid Chemistry; Beaucage, S. L., Bergstrom, D. E., Glick, G. D., Jones, R. A., Eds.; John Wiley & Sons: New York, 2004; Vol. I, pp. 2.10.1-2.10.16.
36. (c) Scaringe, S. A.; Wincott, F. E.; Caruthers, M. H. J. Am. Chem. Soc. 1998, 120, 11820-11821.
37. (a) Zhou, C.; Honcharenko, D.; Chattopadhyaya, J. Org. Biomol. Chem. 2007, 5, 333-343.
38. (b) Zhou, C.; Pathmasiri, W.; Honcharenko, D.; Chatterjee, S.; Barman, J.; Chattopadhyaya, J. Can. J. Chem. 2007, 85, 293-301.
39. Tanaka, S.; Hirakawa, T.; Oishi, K.; Hayakawa, Y.; Kitamura, M. Tetrahedron Lett. 2007, 48, 7320-7322.
40. Matysiak, S.; Fitznar, H.-P.; Schnell, R.; Pfleiderer, W. Helv. Chim. Acta 1998, 81, 1545-1566.
41. Cieślak, J.; Kauffman, J. S.; Kolodziejski, M. J.; Lloyd, J. R.; Beaucage, S. L. Org. Lett. 2007, 9, 671-674.
42. (a) Markiewicz, W. T. J. Chem. Res. (S) 1979, 24-25.
43. (b) Markiewicz, W. T. J. Chem. Res., Miniprint 1979, 181-197.
44. Veeneman, G. H.; Van Der Marel, G. A.; Van Den Eist, H.; Van Boom, J. H. Tetrahedron 1991, 47, 1547-1562.
45. Münch, U.; Pfleiderer, W. Helv. Chim. Acta 2003, 86, 2546-2565.
46. This purification step is critically important. One must ensure that the desired ribonucleoside 2′-acetal is not contaminated with any 3′-acetal to prevent subsequent incorporation of (2′→5′)- internucleotidic phosphodiester linkages into the oligoribonucleotide during solid-phase synthesis.
47. (a) Ti, G. S.; Gaffney, B. L.; Jones, R. A. J. Am. Chem. Soc. 1982, 104, 1316-1319.
48. (b) Jones, R. A. In Olignuclectide synthesis - a practical approach; Gait, M. J., Ed.; IRL Press: Oxford, 1984; pp 23-34.
49. R = 19.6 min) is identical to that of an authentic sample of 4-(N-methylamino)benzyl alcohol that was prepared from the reduction of 4-(N-methylamino)benzoic acid (see ref 25).
50. Carl, P. L.; Chakravarty, P. K.; Katzenellenbogen, J. A. J. Med. Chem. 1981, 24, 479-480.
51. Reese C.B. Org. Biomol. Chem. 2005, 3, 3851-3868 and references therein.
52. Synthetic (3′→5′)UpU is a substrate for BSP but synthetic (2′→5′)UpU is not. Data are presented in the Supporting Information. See also: (a) Giannaris, P. A.; Damha, M. J. Nucleic Acids Res. 1993, 21, 4742-4749.
53. (b) Thayer, J. R.; Rao, S.; Puri, N.; Burnett, C. A.; Young, M. Anal. Biochem. 2007, 361, 132-139.
54. Commercial bovine spleen phosphodiesterase contains some (1% w/w) adenosine deaminase (ADA) as a contaminant. Such a low concentration of ADA in the digestion reaction was sufficient to quantitatively convert adenosine to inosine. This conversion was unambiguously demonstrated by mixing adenosine with BSP/BAP under the conditions used for the digestion of the RNA oligomer. RP-HPLC analysis of the reaction indicated complete conversion of adenosine to inosine, which had a retention time identical to that of a commercial sample of inosine (data shown in the Supporting Information).
55. 2 is employed as an eluent.